CD167 antibodies target the CD167 antigen, also known as discoidin domain receptor 1 (DDR1), a transmembrane tyrosine kinase receptor belonging to the DDR family. DDR1 is activated by binding to collagen in the extracellular matrix, playing a critical role in regulating cell proliferation, differentiation, adhesion, and migration. It is widely expressed in epithelial cells, leukocytes, and certain cancer cells, and is implicated in pathological processes such as fibrosis, inflammation, and tumor progression. Dysregulation of DDR1 signaling has been linked to cancers (e.g., breast, lung, ovarian), neurodegenerative disorders, and fibrotic diseases.
CD167 antibodies are essential tools for studying DDR1's biological functions and mechanisms. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to detect DDR1 expression levels, localization, and activation states in tissues or cell lines. Researchers also employ these antibodies to explore DDR1's role in cancer metastasis, epithelial-mesenchymal transition (EMT), and therapeutic resistance. Additionally, some studies focus on developing anti-DDR1 monoclonal antibodies as potential therapeutic agents to inhibit tumor growth or fibrosis by blocking collagen-induced receptor activation. Due to DDR1's dual role in both physiological and pathological processes, CD167 antibodies remain crucial for advancing research in oncology, immunology, and regenerative medicine.